Trial Profile

A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the Cypher Elite to the Cypher Bx Velocity Sirolimus-Eluting Stent Systems (ELITE)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
Focus Therapeutic Use
Acronyms ELITE
Sponsors Cordis Corporation

Most Recent Events

17 Dec 2013 Planned End Date changed from 1 Jun 2015 to 1 Sep 2014, according to ClinicalTrials.gov record.
17 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to a Cordis Corporation media release. Cordis plans to cease development of the Cypher Elite stent. Approximately 700 patients have been enrolled and will be followed for 5 years.
07 Aug 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com